Manufacturing Patents In Peril After Court Extends Hatch-Waxman “Safe Harbor”
This article was originally published in The Pink Sheet Daily
Executive Summary
In a dispute related to Amphastar/Watson’s generic enoxaparin, a Federal Circuit panel takes an expansive view of the “Bolar Amendment” and finds that certain post-approval activities are protected from infringement claims, including quality control batch testing of commercial product. The decision draws a blistering dissent from the appeals court’s chief judge, who warns the ruling will “render manufacturing method patents worthless.”
You may also be interested in...
Enoxaparin Generic Saga Continues: Momenta's Manufacturing Patent Invalid
Jury verdict comes seven years after Momenta/Sandoz launched generic version of Lovenox; firms sought treble damages from Amphastar for willful infringement of manufacturing process patent.
Enoxaparin Generic Saga Continues: Momenta's Manufacturing Patent Invalid
Jury verdict comes seven years after Momenta/Sandoz launched generic version of Lovenox; firms sought treble damages from Amphastar for willful infringement of manufacturing process patent.
China Looks To Amend Drug Registration Regulation With Bolar Exemption That Favors Generics
China FDA released a draft regulation on drug registration that formalizes the “Bolar Exemption,” but the approach taken is unbalanced, according to experts, and would end up favoring generic competitors.